Trinity BiotechTRIB
About: Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Employees: 380
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more funds holding
Funds holding: 19 [Q1] → 20 (+1) [Q2]
0.14% less ownership
Funds ownership: 1.55% [Q1] → 1.41% (-0.14%) [Q2]
5% less capital invested
Capital invested by funds: $5.96M [Q1] → $5.67M (-$289K) [Q2]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for TRIB.
Financial journalist opinion
Based on 4 articles about TRIB published over the past 30 days